The efficacy analysis of immunotherapy rechallenge after progression from first-line chemo-immunotherapy in advanced non-small cell lung cancer

Puntos clave

• Immunotherapy rechallenge may maintain efficacy after progression from first-line chemo-immunotherapy in advanced non-small cell lung cancer.
• Evidence shows promising outcomes with better disease control compared to traditional approaches.
• Analysis included patients who experienced initial progression but later responded to rechallenge with immunotherapy.
• May enable new treatment pathways for patients failing first-line chemo-immunotherapy, though further validation is needed.